Liquidia Corporation
Moat Score — Liquidia Corporation
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Liquidia's PRINT particle-engineering platform and the patents/regulatory approval underlying YUTREPIA represent genuine, hard-won intellectual property, validated by surviving extended patent litigation with United Therapeutics to reach FDA approval. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a smaller specialty biopharma, Liquidia has no manufacturing or scale cost advantage versus the far larger United Therapeutics. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As a differentiated, FDA-approved therapy for a rare and serious disease with limited alternatives, YUTREPIA likely carries meaningful list-price pricing power, typical of orphan-drug therapeutics, though payer negotiations and competition from United Therapeutics constrain it somewhat. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in pharmaceutical commercialization; one patient's use of YUTREPIA does not make it more valuable to another patient or prescriber. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a PAH/PH-ILD patient is stabilized on a particular treprostinil formulation and delivery method, switching carries real clinical risk and prescriber inertia, creating moderate stickiness once patients are established on YUTREPIA. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The PAH/PH-ILD patient population is small enough that it does not support unlimited competing entrants, but United Therapeutics' entrenched incumbency means the niche is already contested by a dominant player rather than protected for Liquidia. |